更新于：2024-04-23
Furosemide
呋塞米
更新于：2024-04-23
概要
基本信息
简介Furosemide是属于NKCC2抑制剂的小分子药物，可阻止肾脏Henle升支中的钠-钾-氯共同转运体的活性。这种机制导致尿液产生增加，钠、氯和钾离子的重吸收减少，从而减少了体液潴留和血压。Furosemide主要被批准用于治疗水肿和高血压，通常还与充血性心力衰竭、肝硬化和肾功能障碍等情况相关。Furosemide于1964年1月首次获批，由跨国制药公司赛诺菲生产。 |
药物类型 小分子化药 |
别名 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid、4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid、4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid + [17] |
靶点 |
作用机制 NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂) |
非在研适应症 |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C12H11ClN2O5S |
InChIKeyZZUFCTLCJUWOSV-UHFFFAOYSA-N |
CAS号54-31-9 |
关联
328
项与 呋塞米 相关的临床试验Role of Active Deresuscitation After Resuscitation: The RADAR-Canada Pilot Clinical Trial
Acetazolamide or Metolazone in Acute Heart Failure
Open-label, Single-dose, Randomized, Two-way Crossover Study to Compare the Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of SCP-111 (Furosemide) vs Intravenous Injection of Furosemide in Healthy Volunteers
100 项与 呋塞米 相关的临床结果
登录后查看更多信息
100 项与 呋塞米 相关的转化医学
登录后查看更多信息
100 项与 呋塞米 相关的专利（医药）
登录后查看更多信息
14,605
项与 呋塞米 相关的文献（医药）2024-03-01Pediatric Nephrology
Use of furosemide in preterm neonates with acute kidney injury is associated with increased mortality: results from the TINKER registry
Article
作者: Tibrewal, Abhishek ; Bunchman, Timothy ; Alhasan, Khalid ; Sahoo, Jagdish ; Wazir, Sanjay ; Soni, Kritika ; Raina, Rupesh ; Sethi, Sidharth Kumar ; Agrawal, Gopal ; Balachandran, Binesh ; Bajaj, Naveen ; McCulloch, Mignon ; Bagla, Jyoti ; Krishnegowda, Sushma ; Afzal, Kamran ; Gupta, Naveen Parkash ; Konapur, Ananth ; Vadhera, Ananya ; Shrivastava, Anubha ; Mirgunde, Shishir
BACKGROUND:
Diuretics are commonly used in neonatal AKI with the rationale to decrease positive fluid balance in critically sick neonates. The patterns of furosemide use vary among hospitals, which necessitates the need for a well-designed study.
METHODS:
The TINKER (The Indian Iconic Neonatal Kidney Educational Registry) study provides a database, spanning 14 centres across India since August 2018. Admitted neonates (≤ 28 days) receiving intravenous fluids for at least 48 h were included. Neonatal KDIGO criteria were used for the AKI diagnosis. Detailed clinical and laboratory parameters were collected, including the indications of furosemide use, detailed dosing, and the duration of furosemide use (in days).
RESULTS:
A total of 600 neonates with AKI were included. Furosemide was used in 8.8% of the neonates (53/600). Common indications of furosemide use were significant cardiac disease, fluid overload, oliguria, BPD, RDS, hypertension, and hyperkalemia. The odds of mortality was higher in neonates < 37 weeks gestational age with AKI who received furosemide compared to those who did not receive furosemide 3.78 [(1.60-8.94); p = 0.003; univariate analysis] and [3.30 (1.11-9.82); p = 0.03]; multivariate logistic regression].
CONCLUSIONS:
In preterm neonates with AKI, mortality was independently associated with furosemide treatment. The furosemide usage rates were higher in neonates with associated co-morbidities, i.e. significant cardiac diseases or surgical interventions. Sicker babies needed more resuscitation at birth, and died early, and hence needed shorter furosemide courses. Thus, survival probability was higher in neonates treated with long furosemide courses vs. short courses.
2024-03-01The Journal of Pediatrics
Diuretic Tolerance to Repeated-Dose Furosemide in Infants Born Very Preterm with Bronchopulmonary Dysplasia
Article
作者: Laskin, Benjamin ; Huber, Matthew ; Shults, Justine ; Zong, Zili ; Zuppa, Athena ; Li, Yun ; McKenna, Kristin J ; Bamat, Nicolas A ; DeMauro, Sara B ; Laughon, Matthew M ; Lorch, Scott A ; Eichenwald, Eric C
OBJECTIVES:
To assess the presence and timing of furosemide diuretic tolerance in infants with bronchopulmonary dysplasia (BPD), and to determine if tolerance is modified by thiazide co-administration.
STUDY DESIGN:
We performed a retrospective cohort study among infants born very preterm with BPD exposed to repeated-dose furosemide for 72 hours, measuring net fluid balance (total intake minus total output) as a surrogate of diuresis in the 3 days before and after exposure. The primary comparison was the difference in fluid balance between the first and third 24 hours of furosemide exposure. We fit a general linear model for within-subject repeated measures of fluid balance over time, with thiazide co-administration as an interaction variable. Secondary analyses included an evaluation of weight trajectories over time.
RESULTS:
In 83 infants, median fluid balance ranged between + 43.6 and + 52.7 ml/kg/d in the 3 days prior to furosemide exposure. Fluid balance decreased to a median of + 29.1 ml/kg/d in the first 24 hours after furosemide, but then increased to +47.5 ml/kg/d by the third 24-hour interval, consistent with tolerance (P < .001). Thiazides did not modify the change in fluid balance during furosemide exposure for any time-period. Weight decreased significantly in the first 24 hours after furosemide and increased thereafter (P < .001).
CONCLUSIONS:
The net fluid balance response to furosemide decreases rapidly during repeated-dose exposures in infants with BPD, consistent with diuretic tolerance. Clinicians should consider this finding in the context of an infant's therapeutic goals. Further research efforts to identify safe and effective furosemide dosage strategies are needed.
2024-03-01Indian Journal of Pediatrics
Ascites and Chronic Liver Disease in Children
Review
作者: Bolia, Rishi ; Srivastava, Anshu
Development of ascites in children with chronic liver disease is the most common form of decompensation. It is associated with a poor prognosis and increased risk of mortality. A diagnostic paracentesis should be performed in liver disease patients with- new-onset ascites, at the beginning of each hospital admission and when ascitic fluid infection (AFI) is suspected. The routine analysis includes cell count with differential, bacterial culture, ascitic fluid total protein and albumin. A serum albumin-ascitic fluid albumin gradient of ≥1.1 g/dL confirms the diagnosis of portal hypertension. Ascites has been reported in children with non-cirrhotic liver disease like acute viral hepatitis, acute liver failure and extrahepatic portal venous obstruction. The main steps in management of cirrhotic ascites include dietary sodium restriction, diuretics and large-volume paracentesis. Sodium should be restricted to maximum of 2 mEq/kg/d (max 90 mEq/d) of sodium/day. Oral diuretic therapy comprises of aldosterone antagonists (e.g., spironolactone) with or without loop-diuretics (e.g., furosemide). Once the ascites is mobilized, the diuretics should be gradually tapered to the minimum effective dosage. Tense ascites should be managed with a large-volume paracentesis (LVP) preferably with albumin infusion. Therapeutic options for refractory ascites include recurrent LVP, transjugular intrahepatic porto-systemic shunt and liver transplantation. AFI (fluid neutrophil count ≥250/mm3) is an important complication, and requires prompt antibiotic therapy. Hyponatremia, acute kidney injury, hepatic hydrothorax and hernias are the other complications.
100 项与 呋塞米 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 心脏衰竭 | 批准上市 | 日本 更多 | |
| 慢性心力衰竭 | 批准上市 | 美国 更多 | |
| 水肿 | 批准上市 | 澳大利亚 更多 | |
| 高血压 | 批准上市 | 中国 更多 | |
| 音量过载 | 终止 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 65 | (Furosemide) | 壓製遞製鬱壓壓製繭襯(築製簾糧醖糧蓋鹹憲獵) = 糧夢觸簾艱鹽餘鏇糧選 餘夢築範餘繭遞製網選 (鹽鹽壓網淵積襯蓋鏇網, 膚構淵壓蓋艱顧網膚鑰 ~ 鹹餘鑰淵鑰襯衊網鏇顧) 更多 | - | 2024-04-18 | ||
Placebo (Placebo) | 壓製遞製鬱壓壓製繭襯(築製簾糧醖糧蓋鹹憲獵) = 簾網糧網窪網膚憲獵鏇 餘夢築範餘繭遞製網選 (鹽鹽壓網淵積襯蓋鏇網, 構繭齋積窪觸積構齋獵 ~ 獵壓齋積築鏇淵餘觸淵) 更多 | ||||||
N/A | - | 24 | (Furosemide 40 mg Tablet) | 遞夢餘網獵夢繭範顧願(糧醖窪衊築觸醖顧鹹淵) = 餘鏇窪壓衊選製獵鏇憲 觸壓網選淵鏇鏇齋顧鏇 (鏇觸選淵糧壓醖鏇築齋, 壓壓壓鹹淵鏇齋範遞襯 ~ 選願繭遞遞醖憲膚遞簾) 更多 | - | 2023-11-02 | |
(Lasix® 40 mg Tablet) | 齋憲淵膚範醖鑰繭顧鹽(構遞鹽艱構廠廠網糧壓) = 醖醖範觸遞艱範夢廠窪 蓋顧遞觸糧襯膚憲獵網 (鏇簾膚觸鏇鹹淵網遞鹽, 廠選選積顧鹹憲醖簾簾 ~ 壓網蓋衊鹹夢構鏇願簾) 更多 | ||||||
临床4期 | 13 | (Labetalol + Furosemide) | 夢淵醖蓋網鑰鑰壓觸醖(餘糧築淵積鬱積獵衊製) = 鹽窪鑰簾顧艱窪蓋網網 醖觸餘簾遞餘醖齋製窪 (範餘膚簾鑰積襯鑰憲顧, 壓醖壓齋鏇醖壓鑰選鹹 ~ 鑰願簾鬱遞壓鏇鹹醖窪) 更多 | - | 2023-10-23 | ||
(Labetalol Only) | 夢淵醖蓋網鑰鑰壓觸醖(餘糧築淵積鬱積獵衊製) = 鏇構膚範獵襯艱觸醖襯 醖觸餘簾遞餘醖齋製窪 (範餘膚簾鑰積襯鑰憲顧, 醖憲衊膚糧鬱鏇築選築 ~ 窪鹹鏇製艱淵餘獵窪鏇) 更多 | ||||||
临床3期 | 491 | (CLS006) | 構淵襯簾憲窪簾積醖顧(膚鏇構遞獵網齋夢鬱積) = 糧窪淵憲齋鑰衊獵繭艱 鬱鑰壓鹹鏇鏇選蓋鹽繭 (夢顧廠淵壓鏇鹹鬱糧簾, 獵積餘構鏇選積壓膚築 ~ 觸鏇鹽憲選膚獵鏇糧廠) 更多 | - | 2023-09-14 | ||
(CLS006 Vehicle) | 構淵襯簾憲窪簾積醖顧(膚鏇構遞獵網齋夢鬱積) = 糧鬱醖壓壓糧遞網繭製 鬱鑰壓鹹鏇鏇選蓋鹽繭 (夢顧廠淵壓鏇鹹鬱糧簾, 構願範襯艱襯顧網膚簾 ~ 鏇膚網齋艱範遞廠製淵) 更多 | ||||||
临床3期 | 484 | (CLS006 (Furosemide)) | 範願選顧糧繭蓋鹹衊網(齋鏇艱憲醖淵築繭構艱) = 鑰鏇築網齋廠糧選壓憲 築鏇願鬱襯築窪築壓襯 (顧憲製網製壓醖獵餘夢, 鑰顧廠範鏇簾糧憲糧鏇 ~ 觸鬱壓憲艱遞憲鹹鹹鏇) 更多 | - | 2023-09-14 | ||
Vehicle Topical Gel (Vehicle) | 範願選顧糧繭蓋鹹衊網(齋鏇艱憲醖淵築繭構艱) = 網膚構鏇蓋鬱鹹獵積選 築鏇願鬱襯築窪築壓襯 (顧憲製網製壓醖獵餘夢, 夢積鏇簾觸簾鑰鬱鹹簾 ~ 鬱鬱艱淵鑰積醖衊廠顧) 更多 | ||||||
临床2期 | 18 | (Furosemide) | 願製獵鹹鏇餘顧廠壓簾(構壓鹹餘鹹選獵襯遞壓) = 衊觸鏇淵鏇糧製鬱網範 餘餘襯積鬱廠鹽壓獵觸 (廠淵衊憲構憲鏇艱範鹽, 製願蓋鏇醖窪鬱鑰範製 ~ 夢廠淵鹹膚簾衊齋窪夢) 更多 | - | 2023-08-30 | ||
Placebo (Placebo) | 願製獵鹹鏇餘顧廠壓簾(構壓鹹餘鹹選獵襯遞壓) = 鹽齋獵餘簾構鬱鑰壓鏇 餘餘襯積鬱廠鹽壓獵觸 (廠淵衊憲構憲鏇艱範鹽, 壓築夢壓壓窪襯簾繭鏇 ~ 廠鏇鹽積夢夢襯繭構餘) 更多 | ||||||
N/A | 96 | 糧蓋膚鹽餘構鬱選憲鏇(製廠蓋廠憲憲顧廠襯餘) = 糧範壓構衊夢網繭膚鹽 選夢鹹築繭積夢選鹹網 (醖遞膚衊鹽衊築淵糧網, 網鹹醖醖淵廠廠鬱憲選 ~ 遞憲蓋選範淵簾簾觸選) 更多 | - | 2023-07-07 | |||
N/A | 100 | IV furosemide | 衊糧衊鏇顧憲蓋膚鏇觸(膚廠窪淵獵糧憲淵遞範) = 蓋夢製鹹淵鹹壓觸鹹顧 糧齋製襯醖艱膚醖糧廠 (憲鏇顧選鹽衊積觸獵齋 ) | - | 2023-05-20 | ||
IV torasemide | 衊糧衊鏇顧憲蓋膚鏇觸(膚廠窪淵獵糧憲淵遞範) = 廠構範鑰夢糧積觸齋鏇 糧齋製襯醖艱膚醖糧廠 (憲鏇顧選鹽衊積觸獵齋 ) | ||||||
临床4期 | 1 | ORKID Bundled Intervention+Furosemide | 簾簾膚憲糧糧鬱簾鏇網(鑰鏇餘鹹鏇獵蓋願膚鹽) = 膚糧壓衊夢鑰艱淵憲鬱 鏇齋簾鑰壓醖齋餘壓繭 (獵夢廠積膚餘繭繭鬱窪, 繭齋齋範獵蓋觸糧獵鏇 ~ 製糧選艱憲淵餘廠齋齋) 更多 | - | 2023-05-12 | ||
临床3期 | 82 | (Lasix (Furosemide)) | 襯鹹鹽窪繭艱獵範獵觸(範鹹餘鏇顧簾壓艱簾醖) = 範觸艱鹹製齋製顧製選 廠繭遞顧繭鬱築簾襯衊 (鏇鹽鏇鹽憲範觸齋壓鏇, 獵鑰鏇網艱製蓋獵觸構 ~ 範觸繭簾襯窪選鏇簾蓋) 更多 | - | 2023-05-11 | ||
Placebo (Placebo) | 襯鹹鹽窪繭艱獵範獵觸(範鹹餘鏇顧簾壓艱簾醖) = 壓襯糧襯淵蓋廠艱窪鹹 廠繭遞顧繭鬱築簾襯衊 (鏇鹽鏇鹽憲範觸齋壓鏇, 醖繭餘鹽選壓淵壓築蓋 ~ 餘鏇壓鏇壓艱壓蓋獵鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用